Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening

Abstract Butyrylcholinesterase (BChE) plays an important role in the progression of the Alzheimer’s disease. In this study, we used a structure-based virtual screening (VS) approach to discover new BChE inhibitors. A ligand database was filtered and docked to the BChE protein using Glide program. The outcome from VS was filtered and the top ranked hits were thoroughly examined for their fitting into the protein active site. Consequently, the best 38 hits were selected for in vitro testing using Ellman’s method, and six of which showed inhibition activity for BChE. Interestingly, the most potent hit (Compound 4) exhibited inhibitory activity against the BChE enzyme in the low micromolar level with an IC50 value of 8.3 µM. Hits obtained from this work can act as a starting point for future SAR studies to discover new BChE inhibitors as anti-Alzheimer agents.

[1]  E. Perlson,et al.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?* , 2015, Molecular & Cellular Proteomics.

[2]  T. H. Ferreira-Vieira,et al.  Alzheimer's Disease: Targeting the Cholinergic System , 2016, Current neuropharmacology.

[3]  J. Olin,et al.  Galantamine for Alzheimer's disease. , 2004, The Cochrane database of systematic reviews.

[4]  M. Parat,et al.  Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening. , 2016, Journal of medicinal chemistry.

[5]  Thomas A. Halgren,et al.  Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules , 1996, J. Comput. Chem..

[6]  P. Barbarino,et al.  THE STATE OF THE ART OF DEMENTIA RESEARCH: NEW FRONTIERS , 2019, Alzheimer's & Dementia.

[7]  Eugenia Trushina,et al.  Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease , 2017, Journal of Alzheimer's disease : JAD.

[8]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[9]  I. Gulcin,et al.  Synthesis of some tetrahydropyrimidine-5-carboxylates, determination of their metal chelating effects and inhibition profiles against acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase , 2016, Journal of enzyme inhibition and medicinal chemistry.

[10]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[11]  K. Blennow,et al.  Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo , 2011, Neurobiology of Aging.

[12]  Haopeng Sun,et al.  Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. , 2017, European journal of medicinal chemistry.

[13]  T. Tencomnao,et al.  Amyloidosis in Alzheimer's Disease: The Toxicity of Amyloid Beta (Aβ), Mechanisms of Its Accumulation and Implications of Medicinal Plants for Therapy , 2013, Evidence-based complementary and alternative medicine : eCAM.

[14]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[15]  I. Gulcin,et al.  Inhibitory effects of isatin Mannich bases on carbonic anhydrases, acetylcholinesterase, and butyrylcholinesterase , 2016, Journal of enzyme inhibition and medicinal chemistry.

[16]  E. Perry,et al.  Acetylcholine in mind: a neurotransmitter correlate of consciousness? , 1999, Trends in Neurosciences.

[17]  C. Counsell,et al.  Statistical analysis, trial design and duration in Alzheimer's disease clinical trials: a review , 2011, International Psychogeriatrics.

[18]  Mohammad A. Ghattas,et al.  Identification of new inhibitors of Mdm2–p53 interaction via pharmacophore and structure-based virtual screening , 2018, Drug design, development and therapy.

[19]  F. Vallette,et al.  Molecular and cellular biology of cholinesterases , 1993, Progress in Neurobiology.

[20]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[21]  S. Turk,et al.  Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. , 2014, Journal of medicinal chemistry.

[22]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[23]  C. Supuran,et al.  The effect of caffeic acid phenethyl ester (CAPE) on metabolic enzymes including acetylcholinesterase, butyrylcholinesterase, glutathione S-transferase, lactoperoxidase, and carbonic anhydrase isoenzymes I, II, IX, and XII , 2016, Journal of enzyme inhibition and medicinal chemistry.

[24]  Mohammad A Kamal,et al.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. , 2014, CNS & neurological disorders drug targets.

[25]  K. Davis.  Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.

[26]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[27]  S. Stahl.  The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action. , 2000, The Journal of clinical psychiatry.

[28]  K. Rockwood,et al.  Cholinesterase inhibition in Alzheimer's disease: is specificity the answer? , 2014, Journal of Alzheimer's disease : JAD.

[29]  I. Gulcin,et al.  The synthesis of some β-lactams and investigation of their metal-chelating activity, carbonic anhydrase and acetylcholinesterase inhibition profiles , 2016, Journal of enzyme inhibition and medicinal chemistry.

[30]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[31]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[32]  L. Butcher,et al.  Cholinergic systems mediate action from movement to higher consciousness , 2011, Behavioural Brain Research.

[33]  J. Birks,et al.  Rivastigmine for Alzheimer's disease. , 2015, The Cochrane database of systematic reviews.

[34]  T. Nguyen,et al.  Acetylcholinesterase and Butyrylcholinesterase Inhibitory Properties ofFunctionalized Tetrahydroacridines and Related Analogs , 2014 .

[35]  Yutaka Endo,et al.  Development of a Method for Evaluating Drug-Likeness and Ease of Synthesis Using a Data Set in Which Compounds Are Assigned Scores Based on Chemists' Intuition , 2003, J. Chem. Inf. Comput. Sci..

[36]  Steven G Potkin,et al.  Targeting acetylcholinesterase and butyrylcholinesterase in dementia. , 2005, The international journal of neuropsychopharmacology.

[37]  C. Sotriffer,et al.  Structure-Based Search for New Inhibitors of Cholinesterases , 2013, International journal of molecular sciences.

[38]  J. Kirsch,et al.  Fractional diffusion-limited component of reactions catalyzed by acetylcholinesterase. , 1986, Biochemistry.

[39]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[40]  D. Prvulovic,et al.  Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease , 2014, Expert opinion on drug metabolism & toxicology.

[41]  Harald Hampel,et al.  Galantamine for Alzheimer's disease , 2010, Expert opinion on drug metabolism & toxicology.

[42]  D. Holtzman,et al.  The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. , 2012, Cold Spring Harbor perspectives in medicine.